3rd Qtr conf says most of the changes will be finalized in 2013 and layered in 2014--I am expecting big news before Dec 31. Below is the statement from Rose. Could it be that the market is stealing shares now pending possible news?
"At the heart of the optimization program is a commitment to match the company's resources, staff and efforts with near- and long-term opportunities. One element of the optimization program will be a reduction in the workforce. Other elements of the program include the discontinuation of our early-stage drug discovery operations and our decision to seek a partner or partners for the further development of our dengue lead candidate and other preclinical antiviral candidates. We believe such decisions are warranted in order to support efficiently the Arestvyr business and to provide the necessary financial strength and strategic focus to pursue the best growth prospects.
Going forward, we're targeting approximately $6 million in annual cost savings from the optimization program. We expect to implement most of the changes by the end of this year. We expect to layer on the remaining changes during 2014"